Tricida Directors Hit With Securities Suit Over Drug Approval
A Tricida investor lodged a derivative suit against the pharmaceutical company's top brass Thursday, accusing them of hiding from investors that the company's new kidney disease drug was unlikely to garner...To view the full article, register now.
Already a subscriber? Click here to view full article